Published in Nat Struct Mol Biol on August 14, 2011
Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity (2012) 2.30
The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med (2015) 1.42
Biology and significance of the JAK/STAT signalling pathways. Growth Factors (2012) 1.29
Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol (2015) 1.27
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol (2012) 1.25
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov (2012) 1.25
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell (2015) 1.24
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol (2012) 1.12
Ars Moriendi; the art of dying well - new insights into the molecular pathways of necroptotic cell death. EMBO Rep (2014) 1.07
Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl Acad Sci U S A (2014) 1.05
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol (2013) 1.01
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res (2014) 0.99
Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. PLoS One (2012) 0.96
The molecular regulation of Janus kinase (JAK) activation. Biochem J (2014) 0.95
Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest (2013) 0.94
Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. Nat Struct Mol Biol (2014) 0.93
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT (2013) 0.91
Evolution of the JAK-STAT pathway. JAKSTAT (2013) 0.86
JAK/STAT pathway dysregulation in tumors: a Drosophila perspective. Semin Cell Dev Biol (2014) 0.86
Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am (2012) 0.85
Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep (2013) 0.84
Receptor tyrosine kinases with intracellular pseudokinase domains. Biochem Soc Trans (2013) 0.84
Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. Biochem J (2014) 0.83
JAK-STAT in lipid metabolism of adipocytes. JAKSTAT (2013) 0.82
Activation of protein kinase PKR requires dimerization-induced cis-phosphorylation within the activation loop. J Biol Chem (2013) 0.82
The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner. Biochem J (2015) 0.82
Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish. Haematologica (2012) 0.82
NACK is an integral component of the Notch transcriptional activation complex and is critical for development and tumorigenesis. Cancer Res (2014) 0.81
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications. Haematologica (2015) 0.81
In silico identification of AMPylating enzymes and study of their divergent evolution. Sci Rep (2015) 0.81
A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptors. JAKSTAT (2014) 0.80
Acetylation and sumoylation control STAT5 activation antagonistically. JAKSTAT (2012) 0.80
The Drosophila JAK-STAT pathway. JAKSTAT (2013) 0.80
Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. Blood (2015) 0.78
Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2). J Biol Chem (2015) 0.78
The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs (2013) 0.78
Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure. PLoS Comput Biol (2013) 0.78
The Structural Basis for Class II Cytokine Receptor Recognition by JAK1. Structure (2016) 0.78
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A (2015) 0.78
Redox regulation of Janus kinase: The elephant in the room. JAKSTAT (2013) 0.77
Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice. Blood (2012) 0.77
Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. Leukemia (2015) 0.77
Nucleotide-binding mechanisms in pseudokinases. Biosci Rep (2015) 0.77
Two Dictyostelium tyrosine kinase-like kinases function in parallel, stress-induced STAT activation pathways. Mol Biol Cell (2014) 0.76
Crystal Structure of the FERM-SH2 Module of Human Jak2. PLoS One (2016) 0.76
Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele. PLoS One (2013) 0.76
New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. Clin Cancer Res (2016) 0.75
JH2 is active! Nat Rev Mol Cell Biol (2011) 0.75
Kinase signaling and targeted therapy for primary myelofibrosis. Exp Hematol (2016) 0.75
Modeling ETV6-JAK2-induced leukemia: insights from the zebrafish. Haematologica (2012) 0.75
JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways. Exp Hematol (2016) 0.75
Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol (2017) 0.75
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Rep (2015) 0.75
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview. Rev Bras Hematol Hemoter (2015) 0.75
Kinase inactive Tyrosine kinase (Tyk2) Supports Differentiation of Brown fat Cells. Endocrinology (2016) 0.75
Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection. Nat Commun (2016) 0.75
Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms. Pathologe (2016) 0.75
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc (2006) 16.56
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol (2003) 5.77
Emerging roles of pseudokinases. Trends Cell Biol (2006) 4.48
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Protein tyrosine kinase structure and function. Annu Rev Biochem (2000) 3.62
CASK Functions as a Mg2+-independent neurexin kinase. Cell (2008) 3.10
Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci U S A (1993) 2.88
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A (2010) 2.85
Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat Protoc (2006) 2.71
The Jak-STAT pathway. Mol Immunol (2000) 2.63
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A (2009) 2.55
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood (2005) 2.41
Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure (2009) 2.33
Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol (2000) 2.25
The Janus kinases (Jaks). Genome Biol (2004) 2.18
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem (2002) 2.14
Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science (2009) 2.13
Structure and functional characterization of the atypical human kinase haspin. Proc Natl Acad Sci U S A (2009) 1.85
Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure (2004) 1.82
Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell (2003) 1.79
Pseudokinases-remnants of evolution or key allosteric regulators? Curr Opin Struct Biol (2010) 1.76
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood (2005) 1.73
Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol (2004) 1.55
Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol (2001) 1.50
Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol (2004) 1.43
Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol (2000) 1.38
Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling. Mol Cell Biol (2006) 1.23
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med (2010) 1.19
Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol Cell Biol (2006) 1.12
Determination of the transphosphorylation sites of Jak2 kinase. Biochem Biophys Res Commun (2004) 1.03
Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling. Mol Cell Biol (2009) 1.00
Optimized IMAC-IMAC protocol for phosphopeptide recovery from complex biological samples. J Proteome Res (2010) 1.00
JAK2 inhibitors: what's the true therapeutic potential? Blood Rev (2010) 0.97
Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain. Protein Expr Purif (2009) 0.87
Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity. Mol Endocrinol (2010) 0.87
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature (2002) 16.52
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol (2007) 10.24
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol Cell Proteomics (2005) 6.34
Proteomic analysis of post-translational modifications. Nat Biotechnol (2003) 5.87
Quantitative phosphoproteomics applied to the yeast pheromone signaling pathway. Mol Cell Proteomics (2005) 5.07
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol (2012) 4.21
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol (2002) 3.85
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood (2007) 3.52
Phosphoproteomics of the Arabidopsis plasma membrane and a new phosphorylation site database. Plant Cell (2004) 3.51
The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K+ channels. Neuron (2003) 3.50
Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev (2010) 3.49
Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell (2008) 3.29
The matrix peptide exporter HAF-1 signals a mitochondrial UPR by activating the transcription factor ZC376.7 in C. elegans. Mol Cell (2010) 3.26
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
Large-scale analysis of in vivo phosphorylated membrane proteins by immobilized metal ion affinity chromatography and mass spectrometry. Mol Cell Proteomics (2003) 2.98
Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood (2006) 2.88
Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med (2007) 2.85
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood (2006) 2.74
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood (2014) 2.72
Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat Protoc (2006) 2.71
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell (2007) 2.70
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood (2010) 2.61
Oxidative protein folding by an endoplasmic reticulum-localized peroxiredoxin. Mol Cell (2010) 2.51
The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc Natl Acad Sci U S A (2012) 2.45
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood (2007) 2.44
Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics (2009) 2.39
Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood (2011) 2.27
The Janus kinases (Jaks). Genome Biol (2004) 2.18
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem (2002) 2.14
Optimized fast and sensitive acquisition methods for shotgun proteomics on a quadrupole orbitrap mass spectrometer. J Proteome Res (2012) 2.11
Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics (2009) 2.09
The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem (2009) 2.06
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica (2008) 2.05
Identification and verification of novel rodent postsynaptic density proteins. Mol Cell Proteomics (2004) 2.03
SIMAC (sequential elution from IMAC), a phosphoproteomics strategy for the rapid separation of monophosphorylated from multiply phosphorylated peptides. Mol Cell Proteomics (2007) 1.98
Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol (2002) 1.92
A specific p47phox -serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J Clin Invest (2006) 1.92
Guidelines for reporting the use of mass spectrometry in proteomics. Nat Biotechnol (2008) 1.90
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood (2006) 1.89
Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech (2011) 1.87
Analytical strategies for phosphoproteomics. Proteomics (2009) 1.85
Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14. Mol Cell (2005) 1.84
ABRF-PRG03: phosphorylation site determination. J Biomol Tech (2003) 1.83
Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell (2003) 1.79
Mechanism for activation of the growth factor-activated AGC kinases by turn motif phosphorylation. EMBO J (2007) 1.74
Modification-specific proteomics of plasma membrane proteins: identification and characterization of glycosylphosphatidylinositol-anchored proteins released upon phospholipase D treatment. J Proteome Res (2006) 1.71
Canonical and alternate functions of the microRNA biogenesis machinery. Genes Dev (2010) 1.67
Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2. Nat Struct Mol Biol (2008) 1.67
Modification-specific proteomics: strategies for characterization of post-translational modifications using enrichment techniques. Proteomics (2009) 1.66
Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II. EMBO J (2002) 1.65
Protein hydrogen exchange measured at single-residue resolution by electron transfer dissociation mass spectrometry. Anal Chem (2009) 1.65
Proteomic analysis of glycosylphosphatidylinositol-anchored membrane proteins. Mol Cell Proteomics (2003) 1.65
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica (2008) 1.63
Proteomic analyses reveal divergent ubiquitylation site patterns in murine tissues. Mol Cell Proteomics (2012) 1.62
Tudor staphylococcal nuclease is an evolutionarily conserved component of the programmed cell death degradome. Nat Cell Biol (2009) 1.60
Identification of phosphorylation sites in protein kinase A substrates using artificial neural networks and mass spectrometry. J Proteome Res (2004) 1.57
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Crystal structure of a fibroblast growth factor homologous factor (FHF) defines a conserved surface on FHFs for binding and modulation of voltage-gated sodium channels. J Biol Chem (2009) 1.56
Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol (2004) 1.55
Proteasomal adaptation to environmental stress links resistance to proteotoxicity with longevity in Caenorhabditis elegans. Proc Natl Acad Sci U S A (2008) 1.54
Dynamic histone H3 epigenome marking during the intraerythrocytic cycle of Plasmodium falciparum. Proc Natl Acad Sci U S A (2009) 1.54
Proteomic analysis of exfoliation deposits. Invest Ophthalmol Vis Sci (2007) 1.47
Electron transfer dissociation facilitates the measurement of deuterium incorporation into selectively labeled peptides with single residue resolution. J Am Chem Soc (2008) 1.47
Cell cycle-specific UNG2 phosphorylations regulate protein turnover, activity and association with RPA. EMBO J (2007) 1.46
NetPhosYeast: prediction of protein phosphorylation sites in yeast. Bioinformatics (2007) 1.46
Stable isotopic labeling by amino acids in cultured primary neurons: application to brain-derived neurotrophic factor-dependent phosphotyrosine-associated signaling. Mol Cell Proteomics (2008) 1.46
The multifunctional human p100 protein 'hooks' methylated ligands. Nat Struct Mol Biol (2007) 1.46
The sphingolipid long-chain base-Pkh1/2-Ypk1/2 signaling pathway regulates eisosome assembly and turnover. J Biol Chem (2008) 1.45
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica (2008) 1.45
Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123). J Mol Cell Cardiol (2006) 1.45
Proteomics in chromatin biology and epigenetics: Elucidation of post-translational modifications of histone proteins by mass spectrometry. J Proteomics (2012) 1.44
How IRE1 reacts to ER stress. Cell (2008) 1.43
Molecular analysis of the prokaryotic ubiquitin-like protein (Pup) conjugation pathway in Mycobacterium tuberculosis. Mol Microbiol (2010) 1.42
Rare, structurally homologous self-peptides promote thymocyte positive selection. Immunity (2002) 1.41
STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev (2004) 1.41
Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1α-mediated signaling. Autophagy (2011) 1.40
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood (2008) 1.39
Stable isotope labeling of Arabidopsis thaliana cells and quantitative proteomics by mass spectrometry. Mol Cell Proteomics (2005) 1.39
RNA damage and surveillance under oxidative stress. IUBMB Life (2006) 1.39
Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor. Mol Cell (2003) 1.38
Crystal structure of the MuSK tyrosine kinase: insights into receptor autoregulation. Structure (2002) 1.37
Tudor and nuclease-like domains containing protein p100 function as coactivators for signal transducer and activator of transcription 5. Mol Endocrinol (2003) 1.36
Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood (2003) 1.35
Peptide sequencing and characterization of post-translational modifications by enhanced ion-charging and liquid chromatography electron-transfer dissociation tandem mass spectrometry. Anal Chem (2007) 1.35
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica (2008) 1.33
Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation (2004) 1.33